Sorrento Therapeutics, Inc.
SRNE · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $3,715 | $13,707 | $15,685 | $4,749 |
| - Cash | $23,634 | $36,665 | $56,464 | $22,521 |
| + Debt | $134,504 | $237,577 | $169,393 | $294,104 |
| Enterprise Value | $114,585 | $214,619 | $128,614 | $276,332 |
| Revenue | $62,839 | $52,904 | $39,986 | $31,432 |
| % Growth | 18.8% | 32.3% | 27.2% | – |
| Gross Profit | $29,387 | $39,873 | $30,046 | $19,195 |
| % Margin | 46.8% | 75.4% | 75.1% | 61.1% |
| EBITDA | -$539,928 | -$435,987 | -$275,690 | -$308,395 |
| % Margin | -859.2% | -824.1% | -689.5% | -981.1% |
| Net Income | -$572,843 | -$429,012 | -$298,461 | -$359,103 |
| % Margin | -911.6% | -810.9% | -746.4% | -1,142.5% |
| EPS Diluted | -1.37 | -1.46 | -1.3 | -2.56 |
| % Growth | 6.2% | -12.3% | 49.2% | – |
| Operating Cash Flow | -$293,857 | -$281,821 | -$159,536 | -$172,996 |
| Capital Expenditures | -$13,657 | -$8,871 | -$37,579 | -$11,442 |
| Free Cash Flow | -$307,514 | -$290,692 | -$197,115 | -$184,438 |